Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoString Technologies, a provider of life science tools for translational research and developer of molecular diagnostics, has closed $20m in a Series D round of equity financing.
Subscribe to our email newsletter
New investors include GE, BioMed Ventures and Henri Termeer, former Chairman and CEO of Genzyme Corporation.
According to the company, the financing will be used to continue the growth of NanoString’s life science tools business and develop the company’s first molecular diagnostic product, a breast cancer assay based on the PAM50 gene expression signature.
NanoString provides assays for gene expression, miRNA analysis and copy number variation.
The company recently unveiled second generation nCounter system, which includes the hardware upon which the company will pursue regulatory clearance for its breast cancer subtyping assay and other molecular diagnostic assays.